The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects.

Hong-Yuan ShenHai-Long TangYan-Hua ZhengJuan FengBao-Xia Dong Xie-Qun Chen

Published in: Journal of oncology (2022)

Inhibition of PARP1 sensitizes genotoxic agents and represents an important therapeutic approach for MM. These findings provide preliminary evidence for combining PARP1 inhibitors with TMZ for MM treatment.

Keyphrases

dna damage
dna repair
oxidative stress
induced apoptosis
combination therapy